March 2012 PBAC Outcomes - Items awaiting a TGA outcome
PDF Printable Version of March 2012 PBAC Outcomes - Items awaiting a TGA outcome (54 kb)
|
DRUG AND FORM |
DRUG USE AND TYPE |
LISTING REQUESTED BY SPONSOR
|
PBAC RECOMMENDATION
|
|---|---|---|---|
|
Taliglucerase alfa, lyophilised powder for injection, 200 units, Elelyso®
Pfizer Australia Pty Ltd
Major submission (Parallel Process)
|
Gaucher disease |
Section 100 (Highly Specialised Drugs Program) or Life Saving Drugs Program listing for the long-term enzyme replacement therapy for patients with a confirmed diagnosis of Gaucher disease.
|
The PBAC recommendation cannot be made public until the TGA outcome is known. |
